

Brian Huntly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7329983/publications.pdf>

Version: 2024-02-01

161
papers

19,268
citations

34105

52
h-index

11939

134
g-index

184
all docs

184
docs citations

184
times ranked

23526
citing authors

#	ARTICLE	IF	CITATIONS
1	KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia. <i>Blood Advances</i> , 2022, 6, 165-180.	5.2	9
2	Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. <i>Blood</i> , 2022, 139, 2471-2482.	1.4	12
3	Targeting AML at the intersection of epigenetics and signaling. <i>Science Signaling</i> , 2022, 15, eabo0059.	3.6	1
4	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1585-1595.	7.2	24
5	KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. <i>Leukemia</i> , 2021, 35, 1012-1022.	7.2	26
6	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021, 39, 890-901.	1.6	20
7	Sialic acid-binding immunoglobulin-like lectin (Siglec)15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2021, 193, 946-950.	2.5	5
8	Targeting Chromatin Regulation in Acute Myeloid Leukemia. <i>HemaSphere</i> , 2021, 5, e589.	2.7	1
9	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. <i>Molecular Cell</i> , 2021, 81, 4059-4075.e11.	9.7	42
10	Protein condensates provide a platform for controlling chromatin. <i>Nature</i> , 2021, 597, 642-644.	27.8	0
11	Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. <i>Nature Genetics</i> , 2021, 53, 1443-1455.	21.4	19
12	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021, 192, 62-74.	2.5	18
13	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. <i>Blood</i> , 2021, 138, 608-608.	1.4	0
14	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. <i>Blood</i> , 2021, 138, 5031-5031.	1.4	0
15	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	1.4	0
16	Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 508-508.	1.4	1
17	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4041-4041.	1.4	2
18	Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. <i>Cell Metabolism</i> , 2020, 32, 829-843.e9.	16.2	122

#	ARTICLE	IF	CITATIONS
19	BETs Need Greens: Folate Deficiency and Resistance to MYC-Targeted Therapies. <i>Cancer Discovery</i> , 2020, 10, 1791-1793.	9.4	1
20	Dynamic regulation of hypoxia-inducible factor-1 α activity is essential for normal B cell development. <i>Nature Immunology</i> , 2020, 21, 1408-1420.	14.5	40
21	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <i>Current Oncology Reports</i> , 2020, 22, 61.	4.0	21
22	Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML. <i>Nature Communications</i> , 2020, 11, 1407.	12.8	13
23	CML: new tools to answer old questions. <i>Blood</i> , 2020, 135, 2327-2328.	1.4	2
24	Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells. <i>ELife</i> , 2020, 9, .	6.0	26
25	Transcriptional Heterogeneity Governs Cell Fate Diversification during Pre-Leukemia to Leukemia Progression. <i>Blood</i> , 2020, 136, 31-32.	1.4	0
26	Genetic modification of primary human B cells to model high-grade lymphoma. <i>Nature Communications</i> , 2019, 10, 4543.	12.8	36
27	Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11997-12006.	7.1	54
28	Kinase Networks Regulate Metabolism: I'D(H1) Never Have Guessed!. <i>Cancer Discovery</i> , 2019, 9, 699-701.	9.4	0
29	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019, 216, 966-981.	8.5	91
30	Histone modifiers are oxygen sensors. <i>Science</i> , 2019, 363, 1148-1149.	12.6	15
31	Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. <i>Blood</i> , 2019, 134, 2195-2208.	1.4	39
32	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1951.	3.7	17
33	Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML. <i>Clinical Cancer Research</i> , 2019, 25, 460-462.	7.0	2
34	Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction. <i>Blood</i> , 2019, 134, 278-278.	1.4	2
35	Genetic Vulnerabilities of DNMT3AR882H in Myeloid Malignancies. <i>Blood</i> , 2019, 134, 111-111.	1.4	8
36	Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. <i>Blood</i> , 2018, 131, 1639-1653.	1.4	114

#	ARTICLE	IF	CITATIONS
37	Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. <i>Cancer Cell</i> , 2018, 33, 274-291.e8.	16.8	58
38	Novel epigenetic therapies in hematological malignancies: Current status and beyond. <i>Seminars in Cancer Biology</i> , 2018, 51, 198-210.	9.6	22
39	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378.	12.8	60
40	Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML. <i>Cancer Cell</i> , 2018, 34, 533-535.	16.8	2
41	Population dynamics of normal human blood inferred from somatic mutations. <i>Nature</i> , 2018, 561, 473-478.	27.8	427
42	Hematopoietic stem cells made BETter by inhibition. <i>Haematologica</i> , 2018, 103, 919-921.	3.5	0
43	UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. <i>Nature Genetics</i> , 2018, 50, 883-894.	21.4	117
44	Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials. <i>Blood</i> , 2018, 132, 664-664.	1.4	2
45	A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2018, 132, 1682-1682.	1.4	12
46	Single Cell RNA-Seq Characterises Pre-Leukemic Transformation Driven By CEBPA N321D in the Hoxb8-FL Cell Line. <i>Blood</i> , 2018, 132, 3887-3887.	1.4	0
47	Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia. <i>Lancet, The</i> , 2017, 389, S37.	13.7	0
48	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. <i>Nature Cell Biology</i> , 2017, 19, 1093-1104.	10.3	58
49	SRPK1 Is a Therapeutic Vulnerability in Acute Myeloid Leukemia through Its Effects on Alternative Isoforms of Epigenetic Regulators Including BRD4. <i>Blood</i> , 2017, 130, 781-781.	1.4	0
50	Independence of epigenetic and genetic diversity in AML. <i>Nature Medicine</i> , 2016, 22, 708-709.	30.7	5
51	Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. <i>Blood</i> , 2016, 127, 29-41.	1.4	356
52	Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. <i>Blood</i> , 2016, 128, e1-e9.	1.4	49
53	Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. <i>Cell Reports</i> , 2016, 16, 1039-1054.	6.4	34
54	Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. <i>Nature</i> , 2016, 537, 544-547.	27.8	443

#	ARTICLE	IF	CITATIONS
55	A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2016, 17, 1193-1205.	6.4	556
56	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	8.2	92
57	Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors. <i>Blood</i> , 2016, 128, 460-460.	1.4	1
58	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies. <i>Blood</i> , 2016, 128, 5223-5223.	1.4	6
59	Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 103-119.	2.5	45
60	BET bromodomain inhibitors in leukemia. <i>Experimental Hematology</i> , 2015, 43, 718-731.	0.4	33
61	A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. <i>Journal of Experimental Medicine</i> , 2015, 212, 1551-1569.	8.5	35
62	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	27.8	441
63	Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5 +/â leukemia. <i>BMC Cancer</i> , 2015, 15, 585.	2.6	21
64	Functional and Molecular Consequences of the Dnmt3aR882H Mutation in Acute Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 2424-2424.	1.4	3
65	A Crispr/Cas9 Drop-out Screen Identifies Genome-Wide Genetic Valnerubilities in Acute Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 554-554.	1.4	1
66	Loss of BCOR Protein in Development of Acute Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 2433-2433.	1.4	1
67	Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 311-320.	7.2	152
68	The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors. <i>Stem Cells</i> , 2014, 32, 2324-2337.	3.2	83
69	BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. <i>Leukemia</i> , 2014, 28, 88-97.	7.2	70
70	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. <i>Blood</i> , 2014, 124, 13-23.	1.4	139
71	Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. <i>Blood</i> . 2013;121(12):2289-2300.. <i>Blood</i> , 2014, 123, 2901-2901.	1.4	0
72	Modelling Resistance to Emerging Epigenetic Therapies. <i>Blood</i> , 2014, 124, 3546-3546.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Mll-AF4 Induction during Ontogeny Reveals Early Changes in Myeloid and Lymphoid potential and Results in Hematopoietic Malignancies in Adult Mice. <i>Blood</i> , 2014, 124, 892-892.	1.4	0
74	R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies. <i>Blood</i> , 2014, 124, 2342-2342.	1.4	0
75	Somatic <i>Calr</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i> . <i>New England Journal of Medicine</i> , 2013, 369, 2391-2405.	27.0	1,556
76	The Pathogenesis, Diagnosis, and Treatment of Polycythaemia Vera. , 2013, , 135-153.		0
77	HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias. <i>Oncogene</i> , 2013, 32, 5471-5480.	5.9	13
78	Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. <i>Leukemia</i> , 2013, 27, 1820-1825.	7.2	29
79	Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. <i>Genome Research</i> , 2013, 23, 1874-1884.	5.5	128
80	Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2289-2300.	1.4	72
81	An unexpected finding after a fall from a horse. <i>BMJ, The</i> , 2013, 346, f724-f724.	6.0	0
82	The Genomic Landscape of Myeloproliferative Neoplasms: Somatic <i>Calr</i> Mutations in the Majority of <i>JAK2</i> -Wildtype Patients. <i>Blood</i> , 2013, 122, LBA-2-LBA-2.	1.4	1
83	Role of Epigenetic Readers in Pathogenesis and Therapy of Acute Leukemias. <i>Blood</i> , 2013, 122, SCI-20-SCI-20.	1.4	0
84	The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 3732-3732.	1.4	0
85	Modelling Cellular and Molecular Progression Of CML In The Mouse. <i>Blood</i> , 2013, 122, 2706-2706.	1.4	0
86	Recent advances in acute myeloid leukemia stem cell biology. <i>Haematologica</i> , 2012, 97, 966-974.	3.5	128
87	Cancer stem cell definitions and terminology: the devil is in the details. <i>Nature Reviews Cancer</i> , 2012, 12, 767-775.	28.4	599
88	Targeting Epigenetic Readers in Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 647-657.	27.0	363
89	Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 896-900.	1.5	15
90	Disordered Signaling in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1017-1035.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Activity of a Heptad of Transcription Factors Is Associated with Stem Cell Programs and Clinical Outcome in Acute Myeloid Leukaemia. <i>Blood</i> , 2012, 120, 3525-3525.	1.4	0
92	Acute myeloid leukemia: leukemia stem cells write a prognostic signature. <i>Stem Cell Research and Therapy</i> , 2011, 2, 21.	5.5	5
93	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. <i>Nature</i> , 2011, 478, 529-533.	27.8	1,354
94	Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 177-181.	1.4	61
95	Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL. , 2011, , 143-166.		0
96	Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 1610-1621.	1.4	42
97	Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. <i>Blood</i> , 2011, 118, 1041-1051.	1.4	71
98	Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. <i>Laboratory Investigation</i> , 2011, 91, 1298-1303.	3.7	8
99	Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. <i>Cancer Research</i> , 2011, 71, 4117-4129.	0.9	55
100	The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells. <i>Molecular and Cellular Biology</i> , 2011, 31, 5046-5060.	2.3	46
101	Genome-Wide Analysis of Transcriptional Reprogramming in Mouse Models of Acute Myeloid Leukaemia. <i>PLoS ONE</i> , 2011, 6, e16330.	2.5	27
102	JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. <i>Blood</i> , 2010, 116, 1528-1538.	1.4	195
103	Reprogramming of T Cells to Natural Killer-Like Cells upon <i>Bcl11b</i> Deletion. <i>Science</i> , 2010, 329, 85-89.	12.6	294
104	Clinical utility of routine <i>MPL</i> exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. <i>British Journal of Haematology</i> , 2010, 149, 250-257.	2.5	98
105	Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 617-619.	8.2	192
106	A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients. <i>Oncogene</i> , 2010, 29, 5796-5808.	5.9	39
107	Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. <i>Haematologica</i> , 2010, 95, 1642-1650.	3.5	14
108	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. <i>British Journal of Haematology</i> , 2009, 144, 904-908.	2.5	75

#	ARTICLE	IF	CITATIONS
109	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. <i>Blood</i> , 2009, , .	1.4	6
110	Foxo Transcription Factor Activity Is Retained in Quiescent Chronic Myeloid Leukaemia Stem Cells and Activated by Tyrosine Kinase Inhibitors to Mediate "induced-quiescence" in More Mature progenitors.. <i>Blood</i> , 2009, 114, 187-187.	1.4	5
111	Leukemia Stem Cells in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 326-335.	2.2	56
112	Inhibition of the Bcl-x_L Deamidation Pathway in Myeloproliferative Disorders. <i>New England Journal of Medicine</i> , 2008, 359, 2778-2789.	27.0	84
113	Cdx4 Is Dispensable for Murine Hematopoiesis and MLL-AF9 Mediated Leukemogenesis.. <i>Blood</i> , 2008, 112, 1404-1404.	1.4	0
114	Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes. <i>Blood</i> , 2008, 112, 505-505.	1.4	0
115	HOX Gene Regulation in Acute Myeloid Leukemia: CDX Marks the Spot?. <i>Cell Cycle</i> , 2007, 6, 2241-2245.	2.6	26
116	FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress. <i>Cell</i> , 2007, 128, 325-339.	28.9	1,416
117	Targeting cancer stem cells. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 915-927.	3.4	58
118	FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia. <i>Cancer Cell</i> , 2007, 12, 367-380.	16.8	182
119	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007, 117, 1037-1048.	8.2	127
120	Leukemogenic FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitor Cells in a Murine Model of Chronic Myelomonocytic Leukemia.. <i>Blood</i> , 2007, 110, 1613-1613.	1.4	0
121	Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. <i>Blood</i> , 2006, 108, 3548-3555.	1.4	302
122	Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16924-16929.	7.1	69
123	FoxO Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress.. <i>Blood</i> , 2006, 108, 439-439.	1.4	1
124	Cdx4 Upregulates Hox Gene Expression and Generates Acute Myeloid Leukemia Alone and in Cooperation with Meis1a in a Murine Model.. <i>Blood</i> , 2006, 108, 10-10.	1.4	3
125	Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 952-5.	3.5	26
126	An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation. <i>Haematologica</i> , 2006, 91, 1100-4.	3.5	3

#	ARTICLE	IF	CITATIONS
127	Constitutively activated FGFR3 mutants signal through PLC β -dependent and -independent pathways for hematopoietic transformation. <i>Blood</i> , 2005, 106, 328-337.	1.4	38
128	Leukaemia stem cells and the evolution of cancer-stem-cell research. <i>Nature Reviews Cancer</i> , 2005, 5, 311-321.	28.4	564
129	FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. <i>Oncogene</i> , 2005, 24, 7882-7892.	5.9	68
130	FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. <i>Oncogene</i> , 2005, 24, 8259-8267.	5.9	91
131	Summing up cancer stem cells. <i>Nature</i> , 2005, 435, 1169-1170.	27.8	127
132	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. <i>Cancer Cell</i> , 2005, 7, 129-141.	16.8	1,387
133	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell</i> , 2005, 7, 387-397.	16.8	2,695
134	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. <i>Cancer Cell</i> , 2005, 7, 399.	16.8	6
135	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. <i>Blood</i> , 2005, 106, 3377-3379.	1.4	358
136	Lineage Instruction by Oncogenic Tyrosine Kinase Fusions.. <i>Blood</i> , 2005, 106, 643-643.	1.4	0
137	PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14479-14484.	7.1	168
138	Characterization of the imprinted polycomb gene <i>L3MBTL</i> , a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. <i>British Journal of Haematology</i> , 2004, 127, 509-518.	2.5	36
139	Blasts from the past. <i>Cancer Cell</i> , 2004, 6, 199-201.	16.8	30
140	MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. <i>Cancer Cell</i> , 2004, 6, 587-596.	16.8	642
141	The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFR α positive chronic eosinophilic leukemia. <i>Blood</i> , 2004, 103, 2802-2805.	1.4	88
142	AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. <i>Blood</i> , 2004, 104, 551-551.	1.4	2
143	PKC412 Inhibits the ZNF198-FGFR1 Fusion Tyrosine Kinase and Is Efficacious in Treatment of t(8;13)(p11;q12) Associated Stem Cell Myeloproliferative Disease.. <i>Blood</i> , 2004, 104, 2549-2549.	1.4	4
144	Constitutively Activated FGFR3 Mutants Signal through PLC β - Dependent and -Independent Pathways for Hematopoietic Transformation.. <i>Blood</i> , 2004, 104, 1423-1423.	1.4	0

#	ARTICLE	IF	CITATIONS
145	TEL/PDGFR Tyrosine Kinase Fusion Specifically Activates Myeloid Differentiation Programs, and Converts Lymphoid Progenitors into the Myeloid Lineage.. Blood, 2004, 104, 387-387.	1.4	0
146	PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines.. Blood, 2004, 104, 2448-2448.	1.4	1
147	Survival implications of molecular heterogeneity in variant Philadelphia ⁺ chronic myeloid leukaemia. British Journal of Haematology, 2003, 121, 419-427.	2.5	73
148	Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH. Leukemia, 2003, 17, 1419-1421.	7.2	13
149	Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood, 2003, 102, 2205-2212.	1.4	119
150	Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood, 2003, 102, 1160-1168.	1.4	116
151	Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood, 2002, 99, 4547-4553.	1.4	74
152	Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia. Blood, 2002, 99, 2274-2275.	1.4	11
153	Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?. British Journal of Haematology, 2002, 119, 1062-1069.	2.5	47
154	Myeloproliferative disorders. Best Practice and Research in Clinical Haematology, 2001, 14, 531-551.	1.7	39
155	Cytogenetics of chronic myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 553-571.	1.7	36
156	Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood, 2001, 98, 1732-1738.	1.4	228
157	Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classic t(9;22): a report of two cases. British Journal of Haematology, 2001, 113, 439-442.	2.5	9
158	Mutation and methylation analysis of the transforming growth factor β 2 receptor II gene in polycythaemia vera. British Journal of Haematology, 2001, 115, 872-880.	2.5	13
159	The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence <i>in situ</i> hybridization. British Journal of Haematology, 2000, 110, 839-846.	2.5	38
160	Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. Oncogene, 2000, 19, 3902-3913.	5.9	151
161	Unrelated bone-marrow transplantation in adults. Blood Reviews, 1996, 10, 220-230.	5.7	5